Back to Agenda
Assessing the Value of a Cure: Are HTA Approaches and Payment Models Fit for Purpose?
Session Chair(s)
![Koen Torfs](/_Images/member/Generic_Image_Missing-Profile.jpg)
Koen Torfs
Head of Market Access & Pricing
Actelion, Switzerland
In this session we discuss how to prove value, establish a price, payment models
Speaker(s)
Panel discussion
Charlotte Anderberg, PhD, MSc
Dental and Pharmaceutical Benefits Agency, Sweden
Pharmaceutical Assessor
Panel Discussion
Francis Arickx
National Institute for Health and Disability Insurance (RIZIV-INAMI), Belgium
Head of the Directorate Pharmaceutical Policy
![Michael Schlander](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panel discussion
Michael Schlander
German Cancer Research Center (DKFZ), Germany
Head of the Division of Health Economics
![Steve Wooding](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panel discussion
Steve Wooding
Janssen, United States
Head, Global Commercial and Market Access Strategy Organisation
Panel discussion
Olivier Wong, MD
Medi-Qualite Omega, France
CMO
Have an account?